Brain & Mental Health

Brain & Mental Health
  • An Intensive Burst of Exposure Therapy Outperformed Online Self-Help for OCD

    CATEGORY: BRAIN & MENTAL HEALTH

    On one side, a self-guided online therapy program lasting eight weeks. On the other, four consecutive days of intensive, therapist-led treatment. In a German trial of 119 adults with obsessive-compulsive disorder, the four days won decisively: at three months, 61% of people who got the concentrated treatment had responded, compared with 25% of those given the online program, and 42% versus 14% were essentially free of symptoms.1

    Four days, morning to evening

    The concentrated format is called the Bergen 4-day treatment, developed in Norway. After two preparatory sessions, patients spend four consecutive days in a small group, each with their own therapist on hand. The core method is exposure and response prevention. In plain terms, patients deliberately face the situations that trigger their obsessions, like touching a doorknob they fear is contaminated, and practice not performing the compulsion that usually follows. The comparison group worked through an eight-module online cognitive behavioral therapy program at home, on their own, with the same technique taught onscreen. A computer draw decided who got which format. Symptoms were scored on the standard obsessive-compulsive scale at the end of treatment and three months later.

    A gap that didn’t close

    The difference was large at the end of treatment and still large at three months. People in the four-day group also reported bigger improvements in depression symptoms and quality of life. The trial can’t say how the concentrated format compares with standard weekly therapy, its most important unanswered question, because the comparison arm was self-guided software rather than a clinician. Unguided programs are far cheaper and still helped some people. They just helped far fewer.

    Where this fits

    OCD affects roughly 1 to 2 adults in 100, and many wait years between symptoms and effective treatment. An earlier randomized trial in Norway found the same four-day format beat both self-help and a waiting list, with most patients keeping their gains at follow-up.2 This new trial is the format’s first randomized test in another country’s health system, run at a single center in Hamburg, and 119 people is a modest size. Both findings point the same way: the treatment that works for OCD can be compressed into days rather than months without losing its force.

    Key Takeaways

    • Four days of concentrated exposure therapy beat an eight-week self-guided online CBT program for OCD: 61% versus 25% responded at three months.
    • The trial compared the intensive format only against unguided software, so it doesn’t show how four days stack up against standard weekly therapy with a clinician.
    • A prior Norwegian randomized trial of the same format points the same way, though this remains a single-center study of 119 people.

    References

    1. Jelinek L, Wille L, Scheunemann J, et al. Concentrated Exposure Therapy vs Internet-Based Cognitive Behavioral Therapy for Obsessive-Compulsive Disorder: A Randomized Clinical Trial. JAMA Network Open. 2026;9(10):e2639281. link
    2. Launes G, Hagen K, Sunde T, et al. A Randomized Controlled Trial of Concentrated ERP, Self-Help and Waiting List for Obsessive-Compulsive Disorder: The Bergen 4-Day Treatment. Frontiers in Psychology. 2019;10:2500. link

    More from Brain & Mental Health!


  • Against a Standard MS Pill, an Experimental Tablet Cut Relapses Further

    Could a new class of multiple sclerosis pill actually beat an approved therapy, not just match it? That question had a discouraging history. Two large trials now answer it: remibrutinib, an experimental tablet, had relapse rates 35.2% lower in one… Read More →


  • For Early Alzheimer’s, a Common Herpes Drug Fell Short

    The antiviral didn't work. Eighteen months of valacyclovir, a herpes drug taken safely by millions for cold sores and shingles, failed to slow early Alzheimer's disease in a trial of 120 people. People taking it actually declined about 4 points… Read More →


  • Cannabis-Based Medicines Came Up Short for Anxiety, PTSD, and Psychosis

    For anxiety, the trials found nothing. For post-traumatic stress disorder, nothing. For psychotic illnesses like schizophrenia, nothing. Researchers in Australia pooled every randomized trial ever run on cannabinoids, the active compounds in cannabis such as THC and CBD, as treatments… Read More →


  • Cell Phone Use Wasn’t Tied to Higher Brain Cancer Risk

    Does holding a phone to your ear, year after year, raise your risk of brain cancer? The most comprehensive review yet says no. Commissioned by the World Health Organization, an international team combed 63 studies from 22 countries spanning 1994… Read More →


  • The NAD Booster Nicotinamide Riboside Didn’t Slow Early Parkinson’s Disease

    The supplement didn't work. Nicotinamide riboside, a form of vitamin B3 sold around the world as an NAD booster, failed to slow early Parkinson's disease in a year-long trial of 410 people. Those taking it actually finished about 2.7 points… Read More →


  • Adding Bright Morning Light Lifted Remission Rates in Nonseasonal Depression

    Sitting in front of a bright light box each morning nearly doubled the odds of escaping depression. That's the conclusion of a pooled analysis of 11 randomized trials covering 858 adults with depression that had no seasonal pattern: 40.7% of… Read More →


  • Early Parkinson’s Symptoms Eased on a First-of-Its-Kind Daily Pill

    Could one steady pill a day carry early Parkinson's disease, before levodopa enters the picture? That was the question behind TEMPO-2, and the answer came back yes. Over 27 weeks, 304 adults in the first years of the disease took… Read More →


  • Esketamine Nasal Spray Alone Eased Treatment-Resistant Depression

    Two antidepressants, months of waiting, and no real relief. Roughly a third of people treated for major depression know that dead end, and it has a clinical name: treatment-resistant depression. For them, a trial of 378 adults now offers a… Read More →


  • A Single Dose of an LSD-Based Drug Eased Generalized Anxiety

    Can one carefully supervised dose of LSD quiet an anxious mind, and for how long? Researchers at 22 US clinics put that question to a proper test in 198 adults with moderate-to-severe generalized anxiety disorder, the condition in which worry… Read More →